A clinical perspective on minimal residual disease (MRD) assessment in chronic lymphocytic leukemia
1Lymphoma Research Foundation, New York, New York.
Clinical Advances in Hematology & Oncology : H&O
|April 12, 2021
Abstract
No abstract available in PubMed .
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.3K
11:39Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019
11.8K
